Hardikar syndrome (MIM 612726) is a rare multiple congenital anomaly syndrome characterized by facial clefting, pigmentary retinopathy, biliary anomalies, and intestinal malrotation, but with preserved cognition. Only four patients have been reported previously, and none had a molecular diagnosis. Our objective was to identify the genetic basis of Hardikar syndrome (HS) and expand the phenotypic spectrum of this disorder.
We performed exome sequencing on two previously reported and five unpublished female patients with a clinical diagnosis of HS. X-chromosome inactivation (XCI) studies were also performed.
We report clinical features of HS with previously undescribed phenotypes, including a fatal unprovoked intracranial hemorrhage at age 21. We additionally report the discovery of de novo pathogenic nonsense and frameshift variants in MED12 in these seven individuals and evidence of extremely skewed XCI in all patients with informative testing.
Pathogenic missense variants in the X-chromosome gene MED12 have previously been associated with Opitz–Kaveggia syndrome, Lujan syndrome, Ohdo syndrome, and nonsyndromic intellectual disability, primarily in males. We propose a fifth, female-specific phenotype for MED12, and suggest that nonsense and frameshift loss-of-function MED12 variants in females cause HS. This expands the MED12-associated phenotype in females beyond intellectual disability.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
All variants have been deposited into ClinVar, VCV000432691, VCV000280361, VCV000620451, VCV000520705.
Bourbon, H. M. et al. A unified nomenclature for protein subunits of mediator complexes linking transcriptional regulators to RNA polymerase II. Mol. Cell 14, 553–557 (2004).
Harper, T. M. & Taatjes, D. J. The complex structure and function of mediator. J. Biol. Chem. 293, 13778–13785 (2018).
Fant, C. B. & Taatjes, D. J. Regulatory functions of the mediator kinases CDK8 and CDK19. Transcription 10, 76–90 (2019).
Graham, J. M. & Schwartz, C. E. MED12 related disorders. Am. J. Med. Genet. A 161, 2734–2740 (2013).
Allen, B. L. & Taatjes, D. J. The mediator complex: a central integrator of transcription. Nat. Rev. Mol. Cell Biol. 16, 155–166 (2015).
Hsieh, T. H. S. et al. Mapping nucleosome resolution chromosome folding in yeast by micro-C. Cell 162, 108–119 (2015).
Schneider, M. et al. The nuclear pore-associated TREX-2 complex employs mediator to regulate gene expression. Cell 162, 1016–1028 (2015).
Tutter, A. V. et al. Role for Med12 in regulation of Nanog and Nanog target genes. J. Biol. Chem 284, 3709–3718 (2009).
Hong, S. K. et al. The zebrafish kohtalo/trap230 gene is required for the development of the brain, neural crest, and pronephric kidney. Proc. Natl Acad. Sci. USA 102, 18473–18478 (2005).
Shin, C. H. et al. Multiple roles for Med12 in vertebrate endoderm development. Dev. Biol. 317, 467–479 (2008).
Wu, S. Y., de Borsetti, N. H., Bain, E. J., Bulow, C. R. & Gamse, J. T. Mediator subunit 12 coordinates intrinsic and extrinsic control of epithalamic development. Dev. Biol. 385, 13–22 (2014).
Rocha, P. P., Scholze, M., Bleiß, W. & Schrewe, H. Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development 137, 2723–2731 (2010).
Yin, J. W. & Wang, G. The mediator complex: a master coordinator of transcription and cell lineage development. Development 141, 977–987 (2014).
Kim, S., Xu, X., Hecht, A. & Boyer, T. G. Mediator is a transducer of Wnt/β-catenin signaling. J. Biol. Chem. 281, 14066–14075 (2006).
Lesca, G. et al. Clinical and neurocognitive characterization of a family with a novel MED12 gene frameshift mutation. Am. J. Med. Genet. A 161, 3063–3071 (2013).
Bouazzi, H., Lesca, G., Trujillo, C., Alwasiyah, M. K. & Munnich, A. Nonsyndromic X-linked intellectual deficiency in three brothers with a novel MED12 missense mutation [c.5922G>T (p.Glu1974His)]. Clin. Case Reports 3, 604–609 (2015).
Charzewska, A. et al. The power of the mediator complex-expanding the genetic architecture and phenotypic spectrum of MED12 -related disorders. Clin. Genet. 94, 450–456 (2018).
Prontera, P. et al. A novel MED12 mutation: evidence for a fourth phenotype. Am. J. Med. Genet. A 170, 2377–2382 (2016).
Hardikar, W., Smith, A. L., Keith, C. G. & Chow, C. W. Multisystem obstruction with cholestasis, pigmentary retinopathy, and cleft palate: a new syndrome? Am. J. Med. Genet. 44, 13–17 (1992).
Cools, F. & Jaeken, J. Hardikar syndrome: A new syndrome with cleft lip/palate, pigmentary retinopathy and cholestasis. Am. J. Med. Genet. 71, 472–474 (1997).
Poley, J. R. & Proud, V. K. Hardikar syndrome: new features. Am. J. Med. Genet. A 146, 2473–2479 (2008).
Ryan, K. M. et al. Aortic coarctation and carotid artery aneurysm in a patient with hardikar syndrome: cardiovascular implications for affected individuals. Am. J. Med. Genet. A 170, 482–486 (2016).
Nydegger, A., Van Dyck, M., Fisher, R. A., Jaeken, J. & Hardikar, W. Hardikar syndrome: long term outcome of a rare genetic disorder. Am. J. Med. Genet. A 146, 2468–2472 (2008).
Kurosaki, T., Popp, M. W. & Maquat, L. E. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat. Rev. Mol. Cell. Biol. 20, 406–420 (2019).
Schwartz, C. E. et al. The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene. J. Med. Genet. 44, 472–477 (2007).
Clark, R. D. et al. FG syndrome, an X-linked multiple congenital anomaly syndrome: the clinical phenotype and an algorithm for diagnostic testing. Genet. Med. 11, 769–775 (2009).
Rump, P. et al. A novel mutation in MED12 causes FG syndrome (Opitz-Kaveggia syndrome). Clin. Genet. 79, 183–188 (2011).
Lyons MJ. MED12-Related Disorders. 2008 Jun 23 [updated 2016 Aug 11]. In GeneReviews® [Internet]. (eds Adam, M. P. et al.) (Seattle (WA): University of Washington, Seattle, 1993–2020).
Murakami, H., Enomoto, Y., Tsurusaki, Y., Sugio, Y. & Kurosawa, K. A female patient with X‐linked Ohdo syndrome of the Maat‐Kievit‐Brunner phenotype caused by a novel variant of MED12. Congenit. Anom. 60, 91–93 (2019).
Fieremans, N. et al. Identification of Intellectual disability genes in female patients with a skewed X-inactivation pattern. Hum. Mutat. 37, 804–811 (2016).
Wang, C. et al. MED12-related disease in a chinese girl: clinical characteristics and underlying mechanism. Front Genet 11, 129 (2020).
Kosmicki, J. A. et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat. Genet. 49, 504–510 (2017).
Hoffbuhr, K. et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 56, 1486–1495 (2001).
Zito, A. et al. Heritability of skewed X-inactivation in female twins is tissue-specific and associated with age. Nat. Commun. 10, 5339 (2019).
Donnio, L. M. et al. MED12-related XLID disorders are dose-dependent of immediate early genes (IEGs) expression. Hum. Mol. Genet. 26, 2062–2075 (2017).
Srivastava, S. et al. Dysregulations of sonic hedgehog signaling in MED12‐related X‐linked intellectual disability disorders. Mol. Genet. Genomic Med. 7, e00569 (2019).
Ejarque, I. et al. Is Hardikar syndrome distinct from Kabuki (Niikawa—Kuroki) syndrome? Clin. Genet. 80, 493–496 (2011).
Cheng, D. et al. CARM1 methylates MED12 to regulate its RNA-binding ability. Life Sci. Alliance 1, e201800117 (2018).
Aranda-Orgilles, B. et al. MED12 regulates HSC-specific enhancers independently of mediator kinase activity to control hematopoiesis. Cell Stem Cell 19, 784–799 (2016).
Verhagen, J. M. A., Oostdijk, W., Terwisscha van Scheltinga, C. E. J., Schalij-Delfos, N. E. & van Bever, Y. An unusual presentation of Kabuki syndrome: clinical overlap with CHARGE syndrome. Eur. J. Med. Genet. 57, 510–512 (2014).
Schulz Y. et al. CHARGE and Kabuki syndromes: a phenotypic and molecular link. Hum. Mol. Genet. 23, 4396–4405 (2014).
We thank all the patients and families who participated in this study. There are no funders to acknowledge.
The authors declare no competing interests.
All individuals’ families from the different institutions agreed to participate in this study and signed appropriate consent forms. The Institutional Review Board of the Children’s Hospital of Philadelphia approved this study. Permission for clinical photographs was given separately.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, D., Strong, A., Shen, K.M. et al. De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females. Genet Med (2020). https://doi.org/10.1038/s41436-020-01031-7